SCHEMBL5872278

SCHEMBL5872278

COc1ccc2c(c1)N(C1CCNCC1)C(=O)CC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 8/20 0.49
HTR2B P41595 7/20 0.49
HTR2A P28223 4/20 0.41
KYAT1 Q16773 1/20 0.40
KYAT3 Q6YP21 1/20 0.40
AADAT Q8N5Z0 1/20 0.40
HTR3E A5X5Y0 1/20 0.39
HTR3B O95264 1/20 0.39
CHRM4 P08173 1/20 0.39
HTR1A P08908 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
HTR1E P28566 1/20 0.39
AVPR2 P30518 1/20 0.39
OXTR P30559 1/20 0.39
HTR1F P30939 1/20 0.39
HTR7 P34969 1/20 0.39
ADRA1A P35348 1/20 0.39
DRD3 P35462 1/20 0.39
AVPR1A P37288 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10063155 0.88 CHRM2 (0.45) HTR2CHTR2BHTR2AKYAT1KYAT3
SCHEMBL15202987 0.81 HTR2C (0.51) HTR2CHTR2BHTR2AKYAT1KYAT3
SCHEMBL7414811 0.80 HTR2C (0.48) HTR2CHTR2BHTR2AHTR3EHTR3B
SCHEMBL982437 0.78 CHRM2 (0.49) KYAT1KYAT3AADATCHRM4OPRM1
SCHEMBL5871641 0.77 HTR2C (0.65) HTR2CHTR2BHTR2AHTR3EHTR3B
SCHEMBL1238158 0.76 OPRM1 (0.62) OPRM1OPRK1OPRL1
SCHEMBL5871687 0.75 HTR2C (0.70) HTR2CHTR2BHTR2AHTR3EHTR3B
Hydrochloric Acid SCHEMBL2266593 0.75 OPRM1 (0.60) OPRM1OPRK1OPRL1
SCHEMBL6073593 0.73 CYP11B1 (0.52) KYAT1KYAT3AADATDRD3CHRM1
SCHEMBL3597622 0.73 HTR2C (0.38) HTR2CHTR2BOPRM1OPRK1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071201-B2 Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline EISAI CO., LTD. (JP) 2006-07-04 US disclosed
EP-0976732-B1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES EISAI CO LTD (JP) 2004-11-24 EP disclosed
US-6579881-B2 Indoles EISAI CO., LTD. (JP) 2003-06-17 US disclosed
US-6448243-B1 SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA EISAI CO., LTD. (JP) 2002-09-10 US disclosed
US-20020086999-A1 Certain quinoline derivatives EISAI CO., LTD. 2002-07-04 US disclosed
US-20020019531-A1 Indoles EISAI CO., LTD. 2002-02-14 US disclosed
EP-0976732-A1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019531-A1 Indoles INMT, MUSK, MB HTR2C 222/4885HTR2B 91/4885HTR2A 209/4885
US-20020086999-A1 Certain quinoline derivatives CHRM1, CHRNA5, CHRNA4 HTR2C 107/4885HTR2B 45/4885HTR2A 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.